Abstract
Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.
Highlights
In a global effort to combat the COVID-19 pandemic, a diverse number of strategies may reduce viral transmission
A group achieved this in animal models by administering the toll-like receptor-2 (TLR-2) agonist Pam2Cys in mice, in which reduced influenza virus levels in the upper respiratory tract (URT) and lungs were observed [2]
In a study recently published in EBioMedicine, INNA-051, a similar compound, has been shown to potentially serve as a suitable intranasal (i.n.) prophylaxis for SARS-CoV-2 in a ferret challenge model [4]
Summary
In a global effort to combat the COVID-19 pandemic, a diverse number of strategies may reduce viral transmission. In the absence of a distributed vaccine or highly effective antiviral, NPIs form one of the few readily available tactics we can employ to delay and/or reduce the spread. NPIs, have no influence on one’s immunity to SARS-CoV-2, which is attained in one of two ways À infection, or immunisation. As SARSCoV-2 infection probably does not result in lifelong immunity, the necessity for a therapy that might prevent transmission is of importance.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
